使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
And welcome to today's DexCom First Quarter Results Conference Call. Today's call is being recorded. (OPERATOR INSTRUCTIONS) Now I'd like to turn the conference over to Andrew Rasdal, Chief Executive Officer of DexCom. Mr. Rasdal, please go ahead.
歡迎各位參加今天的 DexCom 第一季財報電話會議。今天的會議將進行錄音。(接線員指示)現在我想把會議交給 DexCom 執行長 Andrew Rasdal。Rasdal 先生,請開始。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Great. Well, thanks to everyone for joining us this afternoon for our Q1 update call. As always, I'll turn it over here in just a little bit to Steve Kemper to quickly go through the financials and then come back and provide a more broad over business update. So at this time, I'll turn it over to Steve Kemper, our CFO.
很好。感謝各位今天下午加入我們的第一季更新電話會議。一如往常,我稍後會先把時間交給 Steve Kemper,請他快速說明財務數據,之後我再回來提供更全面的業務更新。那麼現在我把時間交給我們的財務長 Steve Kemper。
Steve Kemper - Chief Financial Officer
Steve Kemper - Chief Financial Officer
Great. Good afternoon, everyone. We will be making forward-looking statements, so please refer to our 10-Q, our 10-K, and all of our SEC filings for a full discussion of the risk factors.
很好。各位下午好。我們將會發表前瞻性陳述,請參閱我們的 10-Q、10-K 以及所有向美國證券交易委員會(SEC)提交的文件,以取得風險因素的完整討論。
DexCom today reported a net loss of $10.9 million for the first quarter of 2007, or $0.39 per share, compared to a net loss of $10.9 million, or $0.43 per share for the first quarter of 2006. Sequentially, our loss declined $144,000 from the fourth quarter of 2006.
DexCom 今日公布 2007 年第一季淨損為 1,090 萬美元,或每股 0.39 美元;相較之下,2006 年第一季淨損同為 1,090 萬美元,或每股 0.43 美元。按季比較,我們的虧損較 2006 年第四季減少 14.4 萬美元。
Today, we reported revenues of just over $1 million for the first quarter of 2007, compared to revenue of $15,000 for the first quarter of 2006 prior to our full launch. Sequentially, we grew revenues 21% with sensor revenues up 15% from the fourth quarter of 2006. We added over 900 new customers during the first quarter after relieving our supply constraints in mid-January. We continue to have good supplies of inventories and have continued to improve our manufacturing operations to allow for more efficient scaling as required. These improvements are just starting to be reflected in our improving gross margin.
今天我們公布 2007 年第一季營收略高於 100 萬美元,相較於 2006 年第一季在全面上市前的 1.5 萬美元營收。按季比較,我們的營收成長 21%,其中感測器營收較 2006 年第四季成長 15%。在 1 月中旬解除供應限制後,我們於第一季新增超過 900 位新客戶。我們持續維持良好的庫存供應,並持續改善製造營運,以便在需要時更有效率地擴大產能。這些改善正開始反映在我們持續改善的毛利率上。
Our gross margin loss of $2.1 million for the first quarter of 2007 was down over $0.5 million sequentially from a loss of $2.6 million during the fourth quarter of 2006. Along with the higher revenue, declining fixed overhead spending and better labor utilization helped improve the gross margin sequentially. So we are very pleased to see the fruits of our recent process improvements in manufacturing starting to result in lower costs.
2007 年第一季毛利損失為 210 萬美元,較 2006 年第四季 260 萬美元的損失按季減少超過 50 萬美元。除了營收提高之外,固定間接費用支出下降與更佳的人力利用率也有助於毛利按季改善。因此,我們很高興看到近期製造流程改善的成果開始帶來成本下降。
Research and development expense decreased $1.5 million to $4 million for the first quarter of 2007, compared to $5.5 million for the first quarter of 2006. Changes in R&D expense include $773,000 in lower clinical and regulatory costs and $873,000 in lower development expenses, partially offset by higher quality assurance costs. Major elements of the declining research and development costs include $458,000 in lower tooling and fixturing costs, $506,000 in lower clinical trial expenses and $286,000 in lower stock-based comp. The tooling and fixturing costs were relatively high in the 2006 quarter as we were then scaling up for our initial product launch. Those expenses have moderated during the first quarter of '07.
2007 年第一季研發費用減少 150 萬美元至 400 萬美元,較 2006 年第一季的 550 萬美元下降。研發費用的變動包括臨床與法規成本減少 77.3 萬美元,以及開發費用減少 87.3 萬美元,但部分被較高的品質保證成本所抵銷。研發成本下降的主要項目包括模具與治具成本減少 45.8 萬美元、臨床試驗費用減少 50.6 萬美元,以及以股票為基礎的薪酬減少 28.6 萬美元。由於 2006 年該季我們正為初次產品上市擴產,模具與治具成本相對較高;這些費用在 2007 年第一季已趨於緩和。
While our clinical costs were lower on a year-to-year basis, we expect these costs to return to previous levels as we move new products and indications through the regulatory cycle.
雖然我們的臨床成本以年度比較呈現下降,但隨著我們推動新產品與新適應症進入法規審查流程,我們預期這些成本將回到先前水準。
Selling, general and administrative expense increased $1.5 million to $5.4 million for the first quarter of 2007, compared to $3.8 million for the first quarter of 2006. The increase was primarily due to $2 million in higher sales and marketing costs, partially offset by approximately $0.5 million in lower general and administrative expenses.
2007 年第一季銷售、一般及行政費用(SG&A)增加 150 萬美元至 540 萬美元,較 2006 年第一季的 380 萬美元上升。增加主要來自銷售與行銷成本增加 200 萬美元,但部分被一般及行政費用約 50 萬美元的下降所抵銷。
Major elements in the increased expense include $1.9 million in higher compensation expense, primarily in sales, and $203,000 in related travel, offset by $545,000 in lower legal expenses and $196,000 in lower recruiting costs. Sequentially, our SG&A was up just $107,000 from the fourth quarter 2006, primarily due to fringe rate expenses that tend to run higher toward the beginning of a calendar year.
費用增加的主要項目包括薪酬費用增加 190 萬美元(主要在銷售部門)以及相關差旅費增加 20.3 萬美元;同時,法律費用減少 54.5 萬美元與招募成本減少 19.6 萬美元形成抵銷。按季比較,我們的 SG&A 較 2006 年第四季僅增加 10.7 萬美元,主要是因為員工福利費率相關費用通常在曆年年初較高。
Net interest income and expense increased $44,000 to $527,000 for the first quarter of 2007, compared to $483,000 for the first quarter of 2006. Increase was due to $309,000 in higher interest income due to our higher cash and investment balances partially offset by $265,000 in interest expense on our convertible debt offering and our capital equipment bank line.
2007 年第一季淨利息收入與費用增加 4.4 萬美元至 52.7 萬美元,較 2006 年第一季的 48.3 萬美元上升。增加原因為因現金與投資餘額較高而帶來利息收入增加 30.9 萬美元,但部分被可轉換公司債發行及資本設備銀行授信額度所產生的利息費用 26.5 萬美元所抵銷。
We ended the quarter with a strong balance sheet. As of March 31, we had $93.2 million in cash and cash equivalents and working capital of just over $89 million. At quarter-end, we had accessed $3.4 million on our bank line to cover capital equipment and leasehold improvement purchases, and we have started repaying that loan on a 30-month amortized basis starting in April.
本季結束時,我們的資產負債表依然強健。截至 3 月 31 日,我們持有現金及約當現金 9,320 萬美元,營運資金略高於 8,900 萬美元。季末時,我們已自銀行授信動用 340 萬美元,用於支付資本設備與租賃裝修改善的採購,並已自 4 月起以 30 個月攤還方式開始償還該筆貸款。
On March 9 of this year, we completed a $60 million offering of 4.75% convertible senior notes due 2027. After payment of related expenses, including the purchase of a related call option hedge, we received net proceeds of $46.6 million. The call option hedge allows us to potentially reduce the dilution associated with the convertible offering if our stock exceeds $7.80 during the next 24 months. It is structured in four tranches with one tranch expiring in each 6-month interval. In effect, we have purchased capped call options that allow us to receive cash or common shares for any amount that our shares exceed $7.80 up to specified caps that range from $9 for the first tranch to $18.50 for the last tranch. At each of the four expiration dates, we can choose to be paid in net shares, effectively taking those shares out of the public (inaudible). Without the call option hedge, we would be issuing approximately 7.7 million shares to convert the $60 million in debt to equity at $7.80 per share. If the call option hedge achieved its full value, the shares issued in conversion would be reduced to approximately 5 million shares, resulting in an effective conversion price of $11.95. We are optimistic about our prospects going forward and believe that the best way to reduce potential dilution related to our convertible financing was to simultaneously purchase the call option hedge.
今年 3 月 9 日,我們完成發行 6,000 萬美元、票面利率 4.75%、到期日為 2027 年的可轉換優先票據。扣除相關費用(包括購買相關的買權避險)後,我們取得淨募資款 4,660 萬美元。該買權避險使我們在未來 24 個月內,若股價超過 7.80 美元,得以潛在降低與此可轉債發行相關的稀釋。其結構分為四個分段(tranche),每 6 個月到期一段。實質上,我們買入了上限式買權(capped call options),使我們得以就股價超過 7.80 美元的部分(至各段指定上限為止)收取現金或普通股;各段上限從第一段的 9 美元到最後一段的 18.50 美元不等。在四個到期日中的每一個,我們可選擇以淨股數方式收取,等同於將那些股份自公開市場中移除(聽不清)。若沒有買權避險,我們將需以每股 7.80 美元將 6,000 萬美元債務轉為股權,約發行 770 萬股。若買權避險達到其全部價值,轉換時發行股數將可降至約 500 萬股,相當於有效轉換價格 11.95 美元。我們對未來展望保持樂觀,並相信降低可轉換融資潛在稀釋的最佳方式,就是同步購買買權避險。
We continue to focus on controlling our expenses and cash burn and are very pleased with the progress of that during the first quarter. Our net cash used in operating activities decreased $2.9 million to $8.4 million for the quarter, compared to $11.3 million for the same period in 2006. During the quarter, we also invested $327,000 in manufacturing and computer equipment and facilities to support primarily manufacturing improvements.
我們持續專注於控制費用與現金消耗,並對第一季在這方面的進展感到非常滿意。本季營運活動所使用的淨現金減少 290 萬美元至 840 萬美元,相較於 2006 年同期的 1,130 萬美元。此外,本季我們也投資 32.7 萬美元於製造與電腦設備及設施,主要用以支援製造改善。
As the result of non-cash expenses, including $1.1 million in stock-based comp, $626,000 in depreciation expenses and about $0.5 million in other payroll-related accruals, our operational cash usage of $8.4 million was much less than our reported net loss of $10.9 million.
由於包含 110 萬美元以股票為基礎的薪酬、62.6 萬美元折舊費用,以及約 50 萬美元其他與薪資相關的應計項目等非現金費用,我們的營運現金使用額 840 萬美元明顯低於所報告的 1,090 萬美元淨損。
That's all for my prepared comments, and I'll now turn it back to Andy Rasdal, our CEO.
以上是我預先準備的評論,現在我把時間交還給我們的執行長 Andy Rasdal。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Great. Thanks, Steve.
很好。謝謝你,Steve。
On the manufacturing and operations front, our efforts to continually improve product quality and supply were very successful in the first quarter. Product complaint rates, especially as they relate to sensor performance, continued their downward trend and are at the lowest since we launched the product approximately a year ago. More importantly, perhaps, qualitative feedback from our field force, from clinicians and patients reinforces that the current product performance is more reliable and consistent. Product supply has been sufficient to support all of our sales and marketing initiatives in the first quarter, and we've not experienced backorder again since we cleared it back in January earlier this year.
在製造與營運方面,我們持續改善產品品質與供應的努力在第一季非常成功。產品客訴率,特別是與感測器效能相關者,持續呈下降趨勢,並已降至約一年前產品上市以來的最低水準。更重要的是,來自我們外勤團隊、臨床醫師與病患的質性回饋也再次證實,目前產品表現更可靠且更一致。第一季的產品供應充足,足以支援我們所有銷售與行銷計畫;自今年 1 月清除積壓訂單後,我們也未再出現缺貨待交(backorder)。
Our improvements have resulted in substantially improving manufacturing yields and throughput which Steve Kemper roughly briefly touched upon as well. We now see sensor yields at our most critical testing point in the 90% range, nearly a three-fold improvement since last fall. As a result, we've been able to reduce our labor pool and costs in our operations. We believe that the decreased product variability that has largely driven these yield improvements is also largely responsible for the improvements in sensor performance of the current product in the field today.
我們的改善已大幅提升製造良率與產出吞吐量,Steve Kemper 也大致簡要提到過。我們目前在最關鍵的測試節點看到感測器良率約在 90% 的區間,較去年秋季幾乎提升近三倍。因此,我們得以縮減營運端的人力規模與成本。我們相信,驅動這些良率改善的主要因素之一是產品變異性降低,而這也在很大程度上解釋了目前市面上產品在感測器效能方面的改善。
But beyond just yield improvements, we've continued to make progress in automating key manufacturing processes to increase throughput, further reduce costs and improve future scalability. We've begun implementing the first of these three process automations which decreases variability, increases our throughput and further decreases direct labor costs in operations, and we continue to methodically invent automation in the other two key processes which further enhance our position. Although of these improvements in the ongoing initiatives are positioning us for significant future scalability to manufacture higher volumes of product as demand may warrant in the future at reduced costs.
但除了僅僅提升良率之外,我們也持續在自動化關鍵製造流程方面取得進展,以提高產出、進一步降低成本並改善未來的可擴展性。我們已開始導入這三項流程自動化中的第一項,該項可降低變異性、提升我們的產出,並進一步降低營運中的直接人工成本;同時,我們也持續有系統地在另外兩項關鍵流程中研發自動化,以進一步強化我們的競爭地位。儘管這些持續推動中的改善措施正使我們具備顯著的未來擴產能力,得以在未來需求需要時,以更低成本製造更高產量的產品。
On the demand and revenue performance front, as Steve said, we added just over 900 new patients in the first quarter, about 10% above the fourth quarter of '06 and in line with our last expectations. Sensor revenues also grew at about 15%, slightly higher than the rate for new patient addition.
在需求與營收表現方面,如 Steve 所說,我們在第一季新增了略高於 900 名新病患,較 2006 年第四季約高出 10%,並符合我們先前的預期。感測器營收也成長約 15%,略高於新增病患的成長率。
Our primary sales and marketing efforts continue to be aimed primarily at creating successful experiences for health care professionals and patients with our CGM products, especially now that we have adequate supply and more consistent sensor performance. We believe our efforts are resulting in health care professionals more often recommending or writing prescriptions for continuous glucose monitoring and the DexCom STS in particular. And while it's difficult to precisely track down data on how many prescriptions are actually written since they may go directly to the patients and not necessarily directly to DexCom at same time, we do have some data points that show prescriptions have begun to outpace patient purchases, which we find encouraging. And so while we'll continue to focus on driving clinical acceptance and utilization primarily at the health care professional level, we're also increasing our efforts to translate prescriptions more readily into patient purchases as well.
我們主要的銷售與行銷工作仍以為醫療專業人員與病患創造使用我們 CGM 產品的成功體驗為核心,尤其是在我們目前供應充足且感測器表現更一致的情況下。我們相信,我們的努力正促使醫療專業人員更常建議或開立連續血糖監測的處方,尤其是 DexCom STS。雖然很難精確追蹤實際開立了多少處方,因為處方可能直接交給病患,而不一定同時直接送達 DexCom,但我們確實有一些數據顯示,處方數已開始超過病患購買數,這讓我們感到鼓舞。因此,雖然我們將持續主要在醫療專業人員層面推動臨床接受度與使用率,我們也正加大力度,讓處方能更順利地轉化為病患的實際購買。
At this time, our rate for actual patient adds continues at about the same rate, and we'd expect that to continue into Q2.
目前,我們實際新增病患的速度仍大致維持在相同水準,我們預期第二季也將延續此趨勢。
We also have begun providing health care professionals with a new version of our software that allows them to download and analyze the CGM data from their patients. This is our Data Manager 2, so this is a second-generation product for health care professionals. The new version of the software is a response to the numerous requests that especially the key thought leaders have had and allows them to more extensively analyze and interpret patient data to help them guide the most appropriate use of CGM to improve glucose control in their respective patient population. It has significantly more extensive analytical and statistical tools to facilitate that.
我們也已開始向醫療專業人員提供新版軟體,使其能下載並分析其病患的 CGM 數據。這是我們的 Data Manager 2,也就是面向醫療專業人員的第二代產品。新版軟體回應了大量需求,尤其是關鍵意見領袖的要求,並使他們能更深入地分析與解讀病患資料,以協助其在各自的病患族群中引導最適當的 CGM 使用方式,進而改善血糖控制。它具備更全面的分析與統計工具,以促進上述工作。
From a marketing perspective, we're primarily using this new software to demonstrate the immediate impact continuous glucose monitoring may have with the site's own patients rather than just rely on published data from other sensors, so it's creating first-hand experiences for both patients and physicians which we believe is key to driving the category in wider utilization by professionals with their patients. We also have the patient version of this new software. It's currently under real-time review at the FDA and we would expect an approval decision soon, perhaps yet in the second quarter.
從行銷角度來看,我們主要利用這套新軟體來展示連續血糖監測對該醫療據點自身病患可能帶來的即時影響,而不只是依賴其他感測器已發表的數據;因此,它為病患與醫師創造第一手的體驗,我們相信這是推動專業人員在其病患中更廣泛使用此類別產品的關鍵。我們也有此新軟體的病患版本。目前該版本正在 FDA 進行即時審查(real-time review),我們預期很快會有核准決定,或許就在第二季內。
From a reimbursement perspective, we're obviously very pleased at CMS's preliminary decision to create [hixpix] codes for continuous glucose monitoring. We are especially appreciative of the leadership that JDRF has provided to that process. An open hearing on these [hixpix] codes was held by CMS in early May. Dr. Lois Jovanovic, one of the most respected thought leaders in diabetes, presented on our behalf and used the forum primarily to address both private and public payers and, I think, provide very compelling data and arguments demonstrating the important role CGM can play in improving diabetes outcome. And so the forum allowed us to not only reach CMS and the people involved with those decisions but, of course, numerous private payers that attend from an information standpoint at those. Medtronic and Abbott, I think( also presented compelling arguments during the open forum their time as well.
在給付(reimbursement)方面,我們對 CMS 初步決定為連續血糖監測建立 [hixpix] 代碼感到非常高興。我們特別感謝 JDRF 在此流程中所提供的領導。CMS 於 5 月初就這些 [hixpix] 代碼舉行了公開聽證會。糖尿病領域最受尊敬的關鍵意見領袖之一 Lois Jovanovic 醫師代表我們發言,並主要利用該場合同時向民間與公部門支付方說明;我認為,她提出了非常有說服力的數據與論點,證明 CGM 在改善糖尿病治療結果方面可扮演的重要角色。因此,該論壇不僅讓我們接觸到 CMS 及參與決策的人員,當然也讓我們從資訊層面接觸到許多出席的民間支付方。我想 Medtronic 與 Abbott 也在公開論壇中提出了有力的論點。
The JDRF-sponsored randomized reimbursement trial is continuing to enroll patients. The design of the trial is obviously very comprehensive and should provide a wide and thorough array of data the payers will find useful for coverage decisions in the future as that data becomes available. Our own outcome study based -- demonstrating statistically significant improvements in A1c levels in 140 patients using the DexCom CGM system has been accepted for peer review publication in the June issue of Diabetes Technology and Therapeutics, which we believe, when combined with our two previous publications demonstrating short-term improvement in glucose control, allows a -- allows us to more aggressively approach payers with compelling clinical and economic set of arguments for short-term and long-term glucose control resulting from continuous glucose monitoring.
由 JDRF 贊助的隨機給付試驗仍在持續招募病患。該試驗設計顯然非常全面,並將在未來數據可用時,提供支付方在做出給付涵蓋決策時會覺得有用的廣泛且完整的資料。我們自身的結果研究——在 140 名使用 DexCom CGM 系統的病患中,顯示 A1c 水準具有統計上顯著的改善——已被《Diabetes Technology and Therapeutics》6 月號接受進行同儕審查發表。我們相信,當這篇文章與我們先前兩篇顯示短期血糖控制改善的發表結合後,將使我們能以更具說服力的臨床與經濟論點,更積極地與支付方溝通,支持連續血糖監測在短期與長期血糖控制上的效益。
We continue to receive unsolicited reports from patients and physicians of favorable coverage decisions, and our own reimbursement organization is currently working to most appropriately build upon these experiences to create wider reimbursement going forward, especially with private payers. We continue to believe that private payers are a very important constituency in diabetes.
我們持續收到病患與醫師主動提供的有利給付涵蓋決策回報,而我們的給付團隊目前正努力在這些經驗基礎上,以最適當的方式推動未來更廣泛的給付,尤其是針對民間支付方。我們仍然相信,民間支付方是糖尿病領域非常重要的關鍵群體。
On the 7-day approval front, we've continue to engage in active and more productive dialogue with the FDA on our PMA supplement to -- for approval of a 7-day sensor. The FDA sent us a written request for additional clarifications which we were able to provide almost immediately with no additional testing or studies, both in writing and in follow-up conversations with the reviewers. In our recent conversations with the FDA, we've largely been discussing labeling, which we interpret as encouraging progress, and although we can't predict the ultimate decisions or timing for a decision by the FDA, based on our most recent conversations, we believe we're still on track for a decision this quarter.
在 7 天核准方面,我們持續就我們的 PMA 補充申請——用於核准 7 天感測器——與 FDA 進行積極且更具成效的對話。FDA 向我們提出書面要求,請提供額外釐清事項;我們幾乎立即就能在不需任何額外測試或研究的情況下,以書面及後續與審查人員的對談提供回覆。在近期與 FDA 的對話中,我們主要在討論標示(labeling),我們將此解讀為令人鼓舞的進展。雖然我們無法預測 FDA 最終決定或決定時點,但根據我們最近的對話,我們相信仍有望在本季取得決定。
We continue to have our belief reinforced that the in-hospital application of continuous glucose monitoring is a very important and large opportunity. Our early efforts in this are generating a great deal of interest, both solicited and unsolicited, at DexCom. We have continued to conduct human feasibility trials with our in-hospital system, and like we did with our STS system a couple years ago, are in the process of rapidly iterating and then trialing the system moving forward. I'm very pleased with the speed and the progress of the project, and we're working to rapidly evolve the technology into a commercial product platform. We expect to engage the FDA shortly to clearly determine the most appropriate regulatory pathway for this product approval, and although it's still too early to accurately predict a commercialization timeline, we're working to best define those paths quickly. We continue to believe the progress we've made and the early data we've generated, this is a meaningful opportunity, and we believe that the in-hospital CGM is a product with and outstanding opportunity for a partnership to most effectively address this important business market segment.
我們持續更加確信,連續血糖監測在院內(in-hospital)的應用是一個非常重要且龐大的機會。我們在此方面的早期努力,已在 DexCom 內部引發大量關注,包含主動與非主動的詢問。我們持續以院內系統進行人體可行性試驗;並且如同幾年前我們對 STS 系統所做的,我們正快速反覆迭代並持續推進試驗。我對該專案的速度與進展非常滿意,我們正努力快速將技術演進為可商業化的產品平台。我們預期不久將與 FDA 接洽,以明確界定此產品核准最適當的法規途徑;雖然目前仍太早無法準確預測商業化時程,但我們正努力盡快把這些路徑定義清楚。我們仍相信,我們已取得的進展與早期數據顯示這是一個有意義的機會;並且我們相信,院內 CGM 是一項非常適合透過合作夥伴關係來最有效切入此重要商業市場區隔的產品,且具備極佳的合作機會。
So I think, in wrapping up, this sort of marks the first full year of commercialization for us. Our first ever product in the first year of commercializing the STS continuous glucose monitoring system, we've learned a great deal about the challenge and opportunities for the CGM category first-hand by providing commercial product to a wide patient population. We believe as much as ever that continuous glucose monitoring will increasingly play an important role in diabetes management and will be a growing and profitable business in the future. We believe we've emerged as a clinical technology leader in the category and we're determined to ensure that DexCom has the presence and staying power to help drive the development of the CGM market and to meaningfully participate as it evolves. And so we remain committed, as we have discussed before, to our three-pronged strategy. First is a continued developing next-generation products with a performance that appeals to larger segments of target populations, including potential partnerships that provide the integration of diabetes management technologies. Second is to create the data experiences and the evidence for health care professionals to widely accept, adopt and prescribe CGM as a primary means for diabetes management. And third, to drive wider spread reimbursement.
因此我想,在總結時,這大致標誌著我們商業化的第一個完整年度。在 STS 連續血糖監測系統商業化的第一年、也是我們史上第一個產品的商業化第一年,我們透過向廣泛的病患族群提供商用產品,第一手學到了許多關於 CGM 類別的挑戰與機會。我們比以往任何時候都更相信,連續血糖監測將在糖尿病管理中扮演日益重要的角色,並在未來成為一項成長且具獲利性的業務。我們相信我們已成為此類別的臨床技術領導者,並決心確保 DexCom 具備市場能見度與長期競爭力,以協助推動 CGM 市場的發展,並在其演進過程中實質參與。因此,我們仍致力於我們先前討論過的三管齊下策略。第一,持續開發下一代產品,其性能能吸引更大範圍的目標族群,並包含可整合糖尿病管理技術的潛在合作夥伴關係。第二,創造數據體驗與證據,使醫療專業人員能廣泛接受、採用並開立 CGM 作為糖尿病管理的主要手段。第三,推動更廣泛的給付涵蓋。
That ends and concludes my prepared remarks. And at this time, we have time to take a couple of calls.
以上是我事先準備的發言內容,至此結束。現在我們有時間接聽幾通來電提問。
Operator
Operator
(OPERATOR INSTRUCTIONS) Our first question will come from Ben Andrew with William Blair.
(接線員指示)我們的第一個問題來自 William Blair 的 Ben Andrew。
Ben Andrew - Analyst
Ben Andrew - Analyst
Hi, Andy. Can you hear me okay?
嗨,Andy。你聽得到我嗎?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Yes. Hi, Ben.
聽得到。嗨,Ben。
Ben Andrew - Analyst
Ben Andrew - Analyst
Just a couple quick questions. You've had kind of a year of experience here. You came off a backlog in the quarter. How do you -- how did you feel about the patient adds after you were off backlog in the quarter versus earlier in the quarter? Did you see a meaningful change there?
我有幾個簡短問題。你們在這裡算是累積了一年的經驗。本季你們消化了先前的積壓訂單(backlog)。在本季解除積壓之後,相較於本季較早的時候,你對新增病患的表現感覺如何?你有看到明顯的變化嗎?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think -- statistically, we were up about 10% or so, but perhaps the most encouraging piece of that there is -- what some data would indicate is an increase in the prescriptions. And so the primary for us there was to regain, rebuild and establish the confidence in both the product and technology with adequate supply and a better-performing product with clinicians, and I think there are some early signs that we're being successful in accomplishing that. And I think patients who are using the products now, both in terms of performance and a year of learning how to best support that and educate and train patients, people overall are happier.
嗯,我認為——從統計上看,我們大約成長了10%左右,但其中最令人鼓舞的一點是——一些數據顯示處方量有所增加。因此,我們在那裡的首要任務是:在供應充足、產品表現更佳的前提下,重新贏回、重建並建立臨床醫師對產品與技術的信心;我認為已有一些早期跡象顯示我們正成功達成這一點。而且我認為,現在正在使用產品的患者,無論就性能表現而言,或是經過一年的學習、了解如何更好地支援並教育與訓練患者而言,整體上大家都更滿意。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And in terms of sales force productivity, has there been any changes to staffing there -- additions, deletions or whatever -- and do you feel like there's an opportunity to make some improvements there by adding staff as you go through the next several quarters?
好的。那就銷售團隊生產力而言,那邊的人力配置是否有任何變動——增員、裁員或其他——而且你是否覺得在接下來幾個季度,隨著業務推進,透過增聘人員有機會做出一些改善?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
I think, as we've said before, one, we've made no changes to the field force of the organization since our last update. We're still at roughly the same numbers. And I think we don't foresee any need to add additional people in the field at this time. I think it's still about bringing up the productivity and driving the fundamental market development acceptance, and then we'll make a reassessment at that time.
我想,正如我們之前說過的,第一,自上次更新以來,我們對組織的前線團隊沒有做任何變動。我們的人數大致維持不變。第二,我們目前也不預期需要在前線再增加人手。我認為重點仍在於提升生產力、推動基本的市場開發與接受度,之後我們會在那個時點再重新評估。
Ben Andrew - Analyst
Ben Andrew - Analyst
Sure. The kind of outlook for Q2 is pretty much -- sounds like steady as she goes in terms of patients adds. Is that a function of, you think, reimbursement? Because obviously, it doesn't appear that the backlog is going to meaningfully change the patient adds here as you come off in -- whatever -- mid-January.
了解。對第二季的展望基本上——聽起來在新增患者數方面會維持平穩。你認為這是報銷的因素嗎?因為很明顯,看起來積壓訂單不會在你們於——不管怎麼說——一月中旬消化完之後,對新增患者數帶來有意義的改變。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Yes. Well, I think, as we've said, based on ongoing rates, the rates for new patient adds are about the same. That's the biggest thing which will drive rapid revenue growth going forward. And I think, outside of a significant event occurring, we'd expect that to continue at that pace. And no, I don't think it's just a reimbursement (inaudible) thing. I still think it's three things. I think, one, next-generation products will be attractive to more patients. Two, continued adoption and clinicians figure out how to best apply this and which patient cohorts have the most benefit from it will drive more. And then third, of course, reimbursement -- takes the economic piece out of the equation. But I don't think it's any one of those things. I think market development shows all three of those are important.
是的。嗯,我想,正如我們所說,基於目前的持續速度,新增患者的增長率大致相同。這是未來推動營收快速成長的最大因素。我認為,除非發生重大事件,否則我們預期會以這樣的速度持續下去。而且不,我不認為這只是報銷(聽不清)方面的因素。我仍然認為有三個因素。第一,下一代產品會吸引更多患者。第二,持續採用,以及臨床醫師逐步摸索出如何最佳應用、哪些患者族群能從中獲得最大效益,將帶動更多使用。第三,當然是報銷——把經濟因素從方程式中移除。但我不認為是其中任何單一因素。我認為市場開發顯示這三者都很重要。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And last question. On the hospital front, you've suggested that you're working on regulatory process and kind of partnership. When do you think we might expect to see developments from FDA and more from (inaudible) final products from DexCom?
好的。最後一個問題。在醫院端,你們提到正在推進法規流程以及某種合作夥伴關係。你認為我們何時可能會看到來自FDA的進展,以及來自DexCom更多(聽不清)的最終產品?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think we're rapidly working through the number of human clinical trials, as I've said, and I think we'll be consistent. What we've done in the past is when we have a meaningful data set that is representative of the product configuration we believe could go through the regulatory path, then either we or our investigators would share the data and the configuration, and I think that really begins then to set the timeline for that. So I think when we have a meaningful data set from a steady state product configuration, that would be time for us to begin to do that.
嗯,我想我們正在快速推進多項人體臨床試驗,正如我所說,我們會保持一致。我們過去的做法是:當我們擁有一組有意義、且能代表我們認為可走法規路徑之產品配置的數據集時,則由我們或研究者分享該數據與配置;我認為那時才真正開始建立相關時程。因此,我認為當我們從穩定狀態的產品配置取得一組有意義的數據集時,就是我們開始這麼做的時機。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. Thanks, Andy.
好的。謝謝你,Andy。
Operator
Operator
Our next question is from Mimi Pham with HSBC.
下一個問題來自HSBC的Mimi Pham。
Mimi Pham - Analyst
Mimi Pham - Analyst
Thank you. First, do you think a significant portion of your install base will upgrade the 7-day system once that's available?
謝謝。首先,你認為你們既有裝機基礎中,會有相當一部分在7天系統上市後升級嗎?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, we don't know, but we would certainly hope so. And we certainly want to take care of our most loyal customers and we'll certainly try to facilitate the best way we can. It is a -- we believe, a clear step forward in product performance and in ease of use and convenience, and so the people who are the heavy users now will be the ones who can clearly benefit the fastest.
嗯,我們不知道,但我們當然希望如此。我們也確實想照顧我們最忠誠的客戶,並會盡力以最佳方式促成。這——我們相信——在產品性能、易用性與便利性方面都是明顯的進步,因此目前的重度使用者將是能最快、最明顯受益的一群。
Mimi Pham - Analyst
Mimi Pham - Analyst
And when you break out the sales, once the 7-day's available, would you be breaking them out as upgrades versus new system sales?
那麼當7天產品上市後,你們在拆分銷售數據時,會把它們區分為升級與新系統銷售嗎?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
I don't know yet.
我現在還不知道。
Mimi Pham - Analyst
Mimi Pham - Analyst
And then for the endocrinologists -- what's the feedback on all the data they're getting? Is it really -- it is possible that it's too much data or --
接著關於內分泌科醫師——他們對所獲得的所有數據有什麼回饋?是否真的——有可能數據太多,或——
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
You mean in terms of the kind of data that the patients --
你的意思是就患者——所得到的那種數據而言——
Mimi Pham - Analyst
Mimi Pham - Analyst
Yes. Yes.
是的。是的。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Actually see? Well, I think, going back five or six years ago, in the continuous field, just like when fingerstick devices replaced urinalysis, the initial response -- the more conservative side -- was this is too much information. The patients won't know what to do with it. And clearly, fingersticks improved the care of diabetes. And I think every publication, we -- and I think Abbott and Medtronic have had -- have showed meaningful improvements in glucose control. As you would expect, the people who manage diabetes are remarkable people, and today they manage with information that is limited and difficult to obtain, and when you give them more better, timely information that's easier to access, they do better. And I think all of our studies indicate that. I would expect that as clinicians find out how to best utilize and create the algorithms and (inaudible) for the best application of CGM, I would expect that would only improve.
實際看到的?嗯,我想回到五、六年前,在連續監測領域,就像指尖採血設備取代尿液分析時一樣,最初的反應——較保守的一方——是:這資訊太多了,患者不知道該怎麼做。但很明顯,指尖採血改善了糖尿病照護。我認為每一篇發表——我們——以及我認為Abbott和Medtronic所做的——都顯示血糖控制有顯著改善。正如你所預期,管理糖尿病的人是非常了不起的群體,而他們今天是在資訊有限且難以取得的情況下進行管理;當你給他們更多、更好、更即時且更容易取得的資訊時,他們就能做得更好。我認為我們所有研究都指出了這一點。我預期,隨著臨床醫師找出如何最佳利用、建立演算法以及(聽不清)以達到CGM的最佳應用,效果只會更好。
Mimi Pham - Analyst
Mimi Pham - Analyst
Thanks. And last question. Do you have any color on the patient attrition rate of the total 3,500 or so systems you've sold? What percent are still ordering sensors and using the system?
謝謝。最後一個問題。你能否提供一些關於你們已售出約3,500套系統的患者流失率的資訊?目前仍在訂購感測器並使用系統的比例是多少?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
We don't, and I think it's just been in the back half of the first quarter that we really got to sort of a steady state supply and (inaudible) begin to look at those things, and so perhaps as we continue in that mode, we'll be able to provide some of that going forward.
我們目前沒有,我想直到第一季後半段,我們才真正達到某種穩定供應狀態並(聽不清)開始去觀察這些事情;因此,或許隨著我們持續維持這種狀態,未來我們就能提供一些相關資訊。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. Thank you.
好的。謝謝。
Operator
Operator
Our next question is from William Plovanic with Canaccord Adams.
下一個問題來自Canaccord Adams的William Plovanic。
William Plovanic - Analyst
William Plovanic - Analyst
Great. Thank you. Good evening. Two things. First of all, just -- we have the ADA coming up. Any papers, posters being presented that we should be aware of and focused on?
很好。謝謝。晚安。兩件事。首先——我們即將迎來ADA年會。有沒有任何論文或海報發表是我們應該注意並聚焦的?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
From our perspective, we'll have two abstracts and one oral presentation, so like we have in the past, largely focused on the 7-day data set. I think probably in June, the more important piece that will be coming out is the fully peer-reviewed data set with 148 patients showing improvements in A1c levels, though.
就我們而言,我們會有兩篇摘要以及一場口頭報告,因此如同以往,主要聚焦在7天的數據集。我認為大概在六月,更重要的是將會發布完整的同儕審查數據集,涵蓋148名患者,顯示A1c水準有所改善。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. And then if I kind of run this through the model, are you still discounting the starter kits or have you pretty much moved off of that and you're pushing closer to a full price on that?
好的。然後如果我把這放進模型裡看,你們是否仍在對入門套件提供折扣?還是你們基本上已經不再那樣做,並把價格推向更接近全價?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
We've never commented on anything but ASP's -- but list prices.
我們從未評論除ASP——也就是標價——以外的任何內容。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. And then if I kind of do the math -- I think Mimi had asked the question, just to kind of jump on that. In terms of usage, how constrained were you for the existing customers that you already had? Like you said, you can't get normal ordering patterns or figure that out, but is there -- was there anything you could discern from the amount of product you had available and the customers you were using? Were they not ordering because there wasn't product available? Were they not ordering because they stopped using the product? Any color would be helpful.
好的。然後如果我做一下數學——我想Mimi問過這個問題,我就接著問。就使用情況而言,你們對既有客戶的供應限制到底有多嚴重?你說你們無法得到正常的訂購模式或判斷,但是否——你們能從可供產品量與正在使用的客戶中看出什麼?他們是不下單因為沒有產品可供?還是不下單因為停止使用產品?任何補充說明都會有幫助。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, unfortunately, the color I can give you probably doesn't help what you're trying to get to, and we would face the same problem. When you're in a backorder situation, especially in a market that's as interconnected as the field of diabetes, patients -- [sure] some get frustrated and maybe don't order. Patients who really want it find that if they place multiple orders and (inaudible) it, then get their allocations faster and more frequently based on that. And so it's really hard to discern anything meaningful until you sort of get to a steady state, and it's both product availability and the consistency of product performance. And I think perhaps going forward, as we get a little more experience, we'll be able to comment on those things in a manner that is responsible.
嗯,不幸的是,我能提供的補充說明可能無法幫到你想要推導的結論,而我們也會面臨同樣的問題。當你處於缺貨待交(backorder)的情況下,尤其是在像糖尿病這樣高度互聯的市場,患者——[當然]有些人會感到挫折,可能就不下單。真正很想要的患者會發現,如果他們下多筆訂單並(聽不清)追蹤,就能更快、更頻繁地依此獲得配額。因此,在你真正達到穩定狀態之前,很難辨識出任何有意義的訊號;而這同時取決於產品可得性與產品性能的一致性。我認為也許未來,隨著我們累積更多經驗,我們就能以負責任的方式對這些事情做出評論。
William Plovanic - Analyst
William Plovanic - Analyst
Okay. Great. Thanks.
好的。很好。謝謝。
Operator
Operator
And we'll next go to Brian Wong with First Albany Capital.
接下來我們轉到First Albany Capital的Brian Wong。
Brian Wong - Analyst
Brian Wong - Analyst
Good afternoon. Thanks for taking my call. I was wondering -- you mentioned that you were automating one of three steps in your manufacturing. I was wondering if you could help us out and let us know when you might get the other two steps up and running?
午安。謝謝接聽我的電話。我想請問——你提到你們正在把製造流程中的三個步驟之一自動化。我想請你們協助說明一下,另外兩個步驟大概何時能夠上線運作?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
We're working methodically through that and we have approvals -- regulatory approvals -- as we've stated previously, to be able to do that, and I think it's making sure that we don't create any quality issues or create any supply issues by being surprised when we put something fully on, so we do it in an integrated style, so I can't provide exact timeframes for that.
我們正有條不紊地推進這件事,而且如同先前所述,我們已取得核准——監管核准——得以這麼做。我認為重點在於確保在全面導入時不會因為措手不及而造成任何品質問題或供應問題,因此我們會以整合式的方式來進行,所以我無法提供確切的時間表。
Brian Wong - Analyst
Brian Wong - Analyst
Would it be within this quarter or would it be later this year?
會是在本季內,還是會在今年稍晚?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Yes.
是。
Brian Wong - Analyst
Brian Wong - Analyst
Alright. And then in terms of getting a coverage decision, do you think you'll ask for one anytime soon, or is just more of a let's see where the payers go case by case?
好。那麼就取得給付涵蓋(coverage)決定而言,你們認為近期會提出申請嗎?還是比較像是看看各個付款方(payer)逐案(case by case)怎麼走?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think we're still consistent with the strategy that we've had. We think it's a meaningful step forward to have the preliminary decision to create codes at the national level through CMS, and that I think will continue to build momentum. We're not in any particular hurry to ask for any sort of large national coverage decision, but rather to build upon the data set that's being generated by us and others, and the experiences patients and physicians are having to build slowly through local regional before beginning to put any sort of national coverage decision. And so the rate at which we and others would move forward, that would be partially dependent upon how we have success from the grass-roots up.
我想我們仍然與既有策略一致。我們認為,透過 CMS 在全國層級做出建立代碼(codes)的初步決定,是一個很有意義的進展,而這也將持續累積動能。我們並不急著去申請任何形式的大型全國性給付涵蓋決定,而是要在我們與其他人所產生的資料集,以及病患與醫師的使用經驗之上逐步累積,先從地方與區域層級慢慢建立,再開始推動任何全國性的給付涵蓋決定。因此,我們與其他人推進的速度,部分將取決於我們能否自下而上、從基層取得成功。
Brian Wong - Analyst
Brian Wong - Analyst
Okay. And I think you've said before that you expected the first decision -- coverage decision -- to come later this year. Are you still agreeing with that statement?
了解。我想你們之前說過,預期第一個決定——給付涵蓋決定——會在今年稍晚出來。你們仍同意這個說法嗎?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I don't know that we stated specifically a timeline for coverage decisions, but I think we have ongoing momentum towards some smaller local and plan-related coverage decisions, and I think probably Medtronic has some of that and more. But I think those will continue to build.
我不確定我們是否曾明確提出給付涵蓋決定的具體時間表,但我認為我們正持續朝向一些較小的、地方性以及與保險計畫相關的給付涵蓋決定累積動能;我想 Medtronic 在這方面可能已有一些、甚至更多。但我認為這些都會持續累積。
Brian Wong - Analyst
Brian Wong - Analyst
Okay. And last question. There was some news that came out recently that on your IR glucose monitor has been developed. I was wondering if you could maybe comment on that would have an impact on your sales or not, or your strategy going forward?
好的。最後一個問題。最近有一些消息指出,你們的 IR(紅外線)葡萄糖監測器已經開發出來了。我想請你們評論一下,這是否會對你們的銷售或未來策略造成影響?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think there have been a number of IR-type devices as well as other noninvasive means of trying to measure glucose that have been available and talked about well over the last 15 years, and whether we'll see one of those come to fruition -- none ever has. And this is another frequency. There's a number of -- I don't know which one you referenced, but there's a number of (inaudible) in both near and mid-IR that have raised money, are being promoted, and so the challenge they have is that they are nonspecific for glucose, and every glucose monitoring device which has ever been commercially successful has been specific for glucose. And so while I think everybody hopes that noninvasive may make testing easier in the future, the technology -- based upon the history -- the technology challenges are substantial.
我想過去 15 年來,市面上一直有多種 IR 類型裝置,以及其他非侵入式量測葡萄糖的方法被提出與討論;至於是否會有其中之一真正落地——至今沒有任何一個成功實現。這只是另一種頻段而已。有不少——我不確定你指的是哪一個——但在近紅外與中紅外領域都有一些(聽不清)公司募到資金、正在推廣。它們面臨的挑戰在於對葡萄糖並不具特異性;而所有曾在商業上成功的葡萄糖監測裝置,都是對葡萄糖具特異性的。因此,雖然大家都希望未來非侵入式技術能讓檢測更容易,但從歷史來看,技術挑戰相當巨大。
Brian Wong - Analyst
Brian Wong - Analyst
Great. Thank you.
很好,謝謝。
Operator
Operator
Our next question is from Steve Ogilvie with ThinkEquity.
下一個問題來自 ThinkEquity 的 Steve Ogilvie。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Hey, guys. Just on the manufacturing, could you maybe comment on -- in terms of time and cost, what it'll take to switch to 7-day?
嗨,各位。關於製造端,能否談談——就時間與成本而言,切換到 7 天版本需要多少投入?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
As we've said before, the 7-day will -- the central piece of it -- will essentially use all of our current equipment, processes and personnel, and we believe that most, if not all, of the improvements we made will be directly transferable to the 7-day. And so I think we're in a much better position starting the 7-day over the 3-day. That being said, look, the introduction of any new product is always -- has its sets of challenges, and we can't foresee all of them. But it's been good, hard discipline in reducing process variability that's gotten us where most of that should be transferable to the 7-day.
如同我們之前所說,7 天版本——其核心部分——基本上會使用我們目前所有的設備、製程與人員,而且我們相信我們所做的大多數(若非全部)改善,都能直接移轉到 7 天版本上。因此,我們在啟動 7 天版本時的起點,比 3 天版本時要好得多。話雖如此,任何新產品的導入一向——都會有其一系列挑戰,我們也無法預見全部。但正是我們在降低製程變異性方面所做的扎實、嚴格的紀律,讓我們走到今天,使得其中大部分應可移轉到 7 天版本。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Okay. And then the other question is, could you maybe comment on the morale of the sales force?
了解。另一個問題是,你能否談談銷售團隊的士氣?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
I haven't had as much interaction as on the last call, where we'd come out of the national sales meeting and I told -- I think I made the comment that I was overwhelmed with the passion and enthusiasm of the field force at that time, and so I think we have a very, very talented group of professionals who in the most part know that it's difficult to pioneer new markets and categories, but when you do so, it's both personally and professionally rewarding.
我和他們的互動不如上次電話會議那麼多;當時我們剛結束全國銷售會議,我也提到——我想我當時的評論是——我被第一線團隊的熱情與投入所震撼。因此,我認為我們有一支非常、非常有才華的專業團隊,他們多半也明白,開拓新市場與新類別是困難的,但一旦成功,無論在個人或職涯上都很有成就感。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Great. Thank you.
很好,謝謝。
Operator
Operator
Our next question is from Caroline Corner with Montgomery and Company.
下一個問題來自 Montgomery and Company 的 Caroline Corner。
Caroline Corner - Analyst
Caroline Corner - Analyst
Hi, guys. Thanks for taking my call. Quick question. When you would plan -- after the 7-day is approved -- when are you going to plan to phase out producing the 3-day? Would that be six months or longer than that?
嗨,各位。謝謝接聽。簡單問一下:在 7 天版本獲准之後,你們打算何時開始逐步停產 3 天版本?會是六個月內,還是更久?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think, as we have stated before, I think the -- we'll sort of let the customer base and the market tell us to some extent. We'll make sure we take care of people. Our belief is it will be fairly rapid and we won't carry on something that doesn't make economic sense, but at the same time, I think we want to be respectful of our current customer base and do that in an orderly and methodical manner. But my belief is it's enough better of a system that it won't continue on for long.
我想,如同我們之前所說,我們會在某種程度上讓客戶基礎與市場來告訴我們。我們會確保照顧到使用者。我們的看法是,轉換會相當快速,我們不會長期維持一個在經濟上不合理的產品;但同時,我們也希望尊重現有客戶群,以有秩序且有條不紊的方式來進行。不過我相信,因為系統改善幅度夠大,所以 3 天版本不會維持太久。
Caroline Corner - Analyst
Caroline Corner - Analyst
And the manufacturing processes you just mentioned -- the 7-day will be all on the current equipment? Can you make them simultaneously to a certain point? The changes in the 7-day, I guess, towards the end of producing the unit? Does that makes sense?
你剛提到的製造流程——7 天版本會完全使用現有設備嗎?你們能在某個階段同時生產兩者嗎?我猜 7 天版本的變更是在單元生產的後段?這樣問有清楚嗎?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, we have the capacity to essentially rotate lines over --
嗯,我們基本上有產能可以把產線輪替切換過去——
Caroline Corner - Analyst
Caroline Corner - Analyst
Okay.
好的。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
So as 7-day comes, we'll roll across it and eliminate 3-day lines as the uptake on that warrants it until ultimately the whole thing would be converted over. So it's not -- yes, so I guess it's simultaneously, although it would be on different lines within the manufacturing environment.
所以當 7 天版本上線後,我們會逐步切換過去,並依其採用(uptake)情況淘汰 3 天版本的產線,直到最終整體都完成轉換。因此——是的,我想可以說是同時進行,雖然會是在製造環境中的不同產線上。
Caroline Corner - Analyst
Caroline Corner - Analyst
Okay. Alright. Good. And then your comments about prescriptions outpacing patient purchases. So you think that the reason for that right now has been the beginning of the quarter there was a little bit of a backorder, and then you've also addressed not only that, but also consistency of the product performance. So also playing into there is a reluctance because of lack of reimbursement? And also, do you feel like there's anything due to patients maybe not being familiar with the products that would be causing pushback from them converting a prescription into a purchase?
了解。好。那你提到處方數量超過病患實際購買。你認為目前造成這種情況的原因,是因為本季初有一點缺貨(backorder),而你們也已經處理了這點,以及產品表現一致性問題。那麼其中也包含因缺乏給付而產生的遲疑嗎?另外,你是否覺得也可能是病患對產品不熟悉,導致他們在把處方轉成實際購買時有所抗拒?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think we see the increased -- or the data points that we have -- this increased rate of prescription as a positive and feedback that our efforts to spend time, to train, to educate and to help health care professionals, the [CD's] and the physicians involved in the care of people with diabetes to understand and most appropriately prescribe and then see the real benefits that provides patients that they can touch on on a fairly short-term basis. And so I think it's positive. I think there's the obvious reasons as to why patients may get a prescription and choose not to fulfill it immediately, but I think we're working methodically through to make sure that we don't make assumptions and we understand exactly what that is and what's required then to be sure that patients do convert those into purchases and utilization of something we believe can help them tremendously in controlling their glucose.
我想我們看到處方增加——或就我們掌握的數據點而言——處方率上升是正面的,這也回饋了我們投入時間去訓練、教育並協助醫療專業人員、[CD's] 以及參與糖尿病照護的醫師,去理解如何最適切地開立處方,並在相對短期內看到能讓病患切身感受到的實際效益。因此我認為這是正面的。當然,病患拿到處方後不立即領藥/購買,原因很明顯可能有很多;但我們正有條不紊地推進,確保不做臆測,而是精確理解原因是什麼,以及接下來需要做什麼,才能確保病患會把處方轉換為購買並實際使用——我們相信這能在控制血糖方面大幅幫助他們。
Caroline Corner - Analyst
Caroline Corner - Analyst
Okay. Great. And then last question. I've seen that in the pump arena, there've been a few kind of recent entrants and more competitive now, like NMS pumps and the OmniPod, the (inaudible) Medtronics pumps out there. Has your sales force seen any evidence of -- with -- if a patient is no longer using a Medtronic pump or is trying something else, is that an easier call for them when they're trying to sell a CGMS system to that patient?
好的,很好。最後一個問題。我看到在胰島素幫浦領域,最近有一些新進者,競爭更激烈了,例如 NMS 幫浦和 OmniPod,以及市面上的(聽不清)Medtronic 幫浦。你們的銷售團隊是否看到任何跡象——如果病患不再使用 Medtronic 幫浦或改用其他產品,這是否會讓你們在向該病患銷售 CGMS 系統時更容易切入?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Not that I'm aware of.
就我所知沒有。
Caroline Corner - Analyst
Caroline Corner - Analyst
Okay. Great. Thanks very much.
好的,很好。非常感謝。
Operator
Operator
Our next question is from Sara Michelmore with Cowen and Company.
下一個問題來自 Cowen and Company 的 Sara Michelmore。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Hi. Good evening. I guess, Andy, I'm a little confused in terms of -- it may just be my misunderstanding, but in terms of the outlook here for new patient starts, are you expecting things to kind of remain at the same pace until you get the 7-day, and should we consider that 7-day as a true trigger in terms of maybe accelerating some of the replacement rates here, or is it going to be a little bit more general than that and just sort of a organic type of growth?
嗨,晚安。我想,Andy,我對於——可能是我理解有誤——對於新病患啟用(new patient starts)的展望有點困惑。你們是否預期在 7 天版本推出前,整體會大致維持相同步調?而我們是否應把 7 天版本視為一個真正的觸發因素(trigger),可能會加速這裡的替換率(replacement rates)?還是會更偏向一般性、比較有機(organic)的成長?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, the only thing I feel comfortable guiding on is the current environment in steady state based upon the rates, and I think we believe that the 7-day approval, if and when it comes, is an important milestone in changing that environment, and it may accelerate those rates, as could product approvals or new product introductions from either of the other companies involved in CGM as well. And so I think remain hopeful and enthusiastic about what the 7-day is. Remain hopeful, enthusiastic that the increase in sort of rates of prescription and some growth with the current product is encouraging, but I think we have to wait and see the data before we can really tell you what the impact of that will be.
嗯,我唯一覺得比較有把握可以提供指引的是,在目前利率所反映的穩態環境下的現況;而我們認為,若且當 7 天核准到來,這將是改變該環境的一個重要里程碑,並且可能會加速那些成長率;同樣地,其他同樣參與 CGM 的公司若有產品核准或新產品推出,也可能帶來加速。因此,我想我們仍對 7 天產品抱持希望與熱情;也仍然希望並樂觀地看待處方開立速度的提升,以及現有產品的一些成長所帶來的鼓舞,但我認為在我們真正看到數據之前,還無法確切告訴你其影響會是什麼。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay. And I know, other than the sensor just being 7 days, you guys have incorporated a decent amount of technology improvements into this product as well. What are the key features that you think make this a better product than what you have on the market currently?
好的。我也知道,除了感測器可使用 7 天之外,你們也在這個產品中納入了相當多的技術改良。你認為有哪些關鍵特點,讓它比你們目前市面上的產品更好?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think the most important one that people will always continue on is more reliable performance over a longer period of time, and clearly the data set that's been published by investigators and now peer reviewed shows strong accuracy -- much-improved accuracy -- especially relative to [YSI] reference for this data set -- and clearly, no decline based upon those measures later, after day 3. And so I think people have a longer period of time of uninterrupted use of more reliable sensor performance. And then I think there's ease of use and convenience that will improve it. For instance, we take the needle size down a full other gauge, which, although in and of itself, wouldn't be a stand-alone product, it still makes it more comfortable and less invasive and easier to insert. We would expect that the shower cover requirement would go away so that people can bathe and shower and do the things they need to do with that, and we've modified, based upon early feedback, some of the software interface screens on the receiver that provide more usability for patients, and so it's -- and it also incorporates a second-generation [ASIC] or microprocessor and transmitter that we also think takes better sensor performance and then does a better job of translating the signal to useable information to the patient.
嗯,我想最重要的一點、也是大家一直會在意的,是在更長時間內更可靠的表現;而且很明顯地,由研究者發表、如今也經同儕審查的數據集顯示出很強的準確度——準確度大幅提升——特別是相對於本數據集的 [YSI] 參考值;並且很清楚地,在第 3 天之後,依據這些衡量指標並沒有出現下降。因此,我認為使用者可以在更長的時間內不中斷地使用,並獲得更可靠的感測器效能。接著我認為在易用性與便利性方面也會有所提升。舉例來說,我們把針頭尺寸再降低一個完整的規格(gauge);雖然單就這一點本身不足以成為一個獨立產品,但它確實讓使用更舒適、更不具侵入性,也更容易插入。我們預期淋浴防護罩的需求會取消,讓人們可以洗澡、淋浴並完成他們需要做的事情;而且我們也根據早期回饋,修改了接收器上的一些軟體介面畫面,為病患提供更好的可用性;此外,它也整合了第二代 [ASIC] 或微處理器與發射器,我們也認為這不僅提升感測器效能,並且能更好地將訊號轉換為病患可用的資訊。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay. That's very helpful. And where are you guys in terms of pursuing a true pediatric label? I know the bar in terms of what the FDA would like for a pediatric product's gone up. What's your latest thoughts there and do you think you actually need to spend the time to do a separate pediatric product?
好的。這非常有幫助。那你們在推進真正的兒科適應症標示方面進展如何?我知道 FDA 對兒科產品的要求門檻提高了。你們目前最新的想法是什麼?你們認為是否真的需要花時間去做一個獨立的兒科產品?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, I think it's -- Medtronic's recent labeling approval's actually very encouraging because the bar looks like it's a bit more reasonable, at least a bit more defined. Sometimes it's nice to have someone go before you and define the path. And so I think now that that's more clearly understood, we continue to move forward. Our desire is not just to take an adult sensor and have pediatric labeling, because our studies have shown that there are differences in the pediatric population. As we've said before, we would expect to introduce a sensor which addresses those differences and is specific for the pediatric. We're currently in a set of feasibility trials, participating also in the JDRF initiative, in their trial. And I would expect that as we see that data and gain that experience, then we'll firm up our plans to actually then seek approval based upon studies for that indication.
嗯,我想——美敦力最近的標示核准其實非常令人鼓舞,因為看起來門檻更合理一些,至少也更明確一些。有時候有人先走在前面把路徑定義出來是件好事。因此,既然現在更清楚了,我們會持續推進。我們的目標不只是拿成人感測器去取得兒科標示,因為我們的研究顯示兒科族群確實存在差異。正如我們之前所說,我們預期會推出一款能解決這些差異、且專為兒科設計的感測器。我們目前正在進行一系列可行性試驗,也參與 JDRF 的倡議與其試驗。我預期當我們看到那些數據並累積經驗後,就會更明確地制定計畫,進而根據針對該適應症的研究來尋求核准。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay. And then in terms of the hospital product, just for my own edification, if you can talk about what are the different product features or key differences in that product that you guys have to address? I know that there's some different needs in that setting. If you can just kind of compare and contrast what appropriate products in the hospital setting would look like compared to what you've done on the consumer side. Thanks.
好的。那再談到醫院用產品,純粹為了我自己了解,如果你能談談你們在那個產品上需要處理的不同產品特性或關鍵差異是什麼?我知道在那種場域有一些不同需求。如果你能大致比較一下,醫院場域中合適的產品應該長什麼樣子,與你們在消費者端所做的相比有哪些不同。謝謝。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Yes, sure. I think the -- we clearly have been working actively in clinical studies for a period of time now with a variety of hospital configurations, and you're exactly right, the challenges -- the technology challenges -- are different than the ambulatory population, largely because of the environment and the differences in those patient populations. The product perform we're developing is aimed specifically at the critical care arenas of the hospitals, specifically the postsurgical ICU where there's such compelling data from [Vandenburg] and [Fernarri] and others about both the improvements in mortality and morbidity, as well as economic benefit, and so we've said previously, the product is an IV-based product which is consistent with the practice -- applied consistently with the practice today in the ICU, and then would continuously sense glucose and then report it in very much the same manner with continuous data, single point values, continuous trends. But as we've learned in the critical care environment, very much providing a set of alarms and parameters so that the nursing stations can respond appropriately.
好的,當然。我想——我們顯然已經在各種醫院配置下,積極進行臨床研究一段時間了;你說得完全正確,挑戰——技術上的挑戰——與門診族群不同,主要是因為環境以及病患族群差異。我們正在開發的產品是專門針對醫院的重症照護領域,特別是術後 ICU;在那裡,[Vandenburg]、[Fernarri] 等人提供了非常有說服力的數據,顯示不僅能改善死亡率與罹病率,也帶來經濟效益。因此我們先前也說過,該產品是一個以靜脈(IV)為基礎的產品,符合目前 ICU 的臨床作業方式,並能持續感測葡萄糖,然後以非常類似的方式回報:連續數據、單點數值、連續趨勢。但我們在重症照護環境中學到的是,必須提供一套警報與參數設定,讓護理站能夠做出適當回應。
Operator
Operator
Sara, did you have a follow-up?
Sara,你有要追問的嗎?
Sara Michelmore - Analyst
Sara Michelmore - Analyst
No. I'm all set. Thank you.
沒有。我都了解了。謝謝。
Operator
Operator
Our next question is from Alex Arrow with Lazard Capital Markets.
下一個問題來自 Lazard Capital Markets 的 Alex Arrow。
Alex Arrow - Analyst
Alex Arrow - Analyst
Thanks. Hi. Andy, could you address the expectation for the dollar amount of the reimbursement that you're looking to get once the amount is finalized by CMS (inaudible)?
謝謝。你好。Andy,你能否談談一旦 CMS 最終確定金額後,你們期望取得的給付(reimbursement)美元金額大概是多少(聽不清)?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Well, they don't -- at this time, I don't think we have any comment on what it is. We have said generically that we think continuous brings great value based upon the data sets us and others provide, but we haven't begun to negotiate a price or make any comment on that relative to either private or public payers.
嗯,他們不——就目前而言,我想我們對那個金額沒有任何評論。我們只是概括地說,根據我們與其他人提供的數據集,我們認為連續監測帶來很大的價值;但我們尚未開始就價格進行協商,也沒有就私營或公共支付方對此做任何評論。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. Without naming the specific number, can you say whether you would expect that it would fully cover the cost of patients using the device or whether they would have to pay some out of pocket even after getting reimbursed?
好的。不用說出具體數字,你能否說明你是否預期該給付會完全涵蓋病患使用該裝置的成本,或是即使獲得給付後,病患仍需要自付一部分?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Yes. I would certainly -- I think you'd get the same answer from all three of the companies in it. There's certainly -- it's really patients who benefit from reimbursement. This is important technology, and we certainly are working hard to be sure that patients don't have to make a decision as to whether they adopt or not based solely on economics and our desire would be to get as much of the reimbursed as close to 100% as possible, but I think other diabetes products certainly indicate that patients will welcome any help at all, and that begins to create the opportunity for deeper and broader adoption as well.
可以。我當然——我想你也會從這三家公司都得到相同的答案。確實——真正受益於給付的是病患。這是一項重要的技術,我們也確實努力確保病患不必僅因經濟因素就決定是否採用;我們的目標是讓給付覆蓋率盡可能接近 100%。但我想其他糖尿病產品也顯示,病患會歡迎任何形式的協助,而這也開始創造更深、更廣泛採用的機會。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. Thanks. Could you then also -- as my follow-up question -- comment a bit on the competitive environment? Number one, the Guardian RT now has supposedly better features than just the Guardian -- or the Real Time versus just the older version of the RT. And also, the second part of that question is what you've been hearing about the timing of the Navigators since we haven't heard much from Abbott.
好的,謝謝。那也請你——作為我的追問——談談競爭環境。第一,Guardian RT 現在據說比 Guardian——也就是 Real Time 相較於舊版 RT——有更好的功能。第二部分是,因為我們很少聽到 Abbott 的消息,你們聽到的 Navigator 時程大概是什麼?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
I can comment, I think, specifically to Medtronic, especially with the introduction of their approval and the introduction of the Minilink, which I think is a much-improved product, more useable certainly from a continuous glucose monitoring, and as expected, they continue to use CGM as a way to, I think, very successfully drive their pump franchise. And again, as you might expect, we see them as a very responsible and appropriate competitor in helping to build the marketplace appropriately for CGM as a tool going forward. Relative to Abbott, I think you probably have the same access to the public information. We don't have any more or less than that, and so I'd have to refer you back to them for anything real specific about the timing.
我想我可以評論,特別是針對美敦力;尤其在他們取得核准並推出 Minilink 之後,我認為那是一個大幅改良的產品,從連續血糖監測的角度來看更可用。而且如同預期,他們持續把 CGM 作為一種方式,我認為非常成功地帶動他們的胰島素幫浦業務。同樣地,如你所預期,我們把他們視為非常負責任且合適的競爭對手,能協助以正確方式建立 CGM 作為未來工具的市場。至於 Abbott,我想你可能也能取得相同的公開資訊。我們並沒有比那更多或更少的資訊,因此任何關於時程的具體細節,我得請你回去詢問他們。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. So Medtronic is better, but is it -- have you lost any accounts to them as a result of their new device? Can you say?
好的。所以美敦力更好,但它——你們是否因為他們的新裝置而流失了任何客戶?你能說嗎?
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
No. I think in the insulin-requiring population of close to 5 million patients, there's plenty of room for all of us.
沒有。我認為在需要胰島素的、接近 500 萬名病患族群中,對我們所有人來說都有很大的空間。
Alex Arrow - Analyst
Alex Arrow - Analyst
Alright. Thanks, Andy.
好。謝謝你,Andy。
Operator
Operator
There are no further questions in the queue. I'd like to turn the call to Andrew Rasdal for additional or closing remarks.
目前佇列中沒有其他問題。我想把電話交給 Andrew Rasdal,請他做補充或結語。
Andrew Rasdal - Chief Executive Officer
Andrew Rasdal - Chief Executive Officer
Great. And we'll just close up by thanking everybody for their time, and we look forward to speaking with you at the next quarterly call.
很好。我們就以感謝各位撥冗參與作結,並期待在下一次季度電話會議再與各位交流。